Table 3.
Hazards for triple-negative cancer (TNC) relapse-free survival (RFS) in the entire cohort with univariate and multivariate analyses
| Clinicopathological feature | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95.0% CI | P value* | HR | 95.0% CI | P value* | ||
| Age (< 60 vs. ≥ 60) | 0.323 | 0.087–1.193 | 0.090 | ||||
| Tumor size (2 cm vs. > 2 cm) | 2.527 | 0.807–7.915 | 0.111 | ||||
| Histological grade (I, II vs. III) | 2.149 | 0.520–8.871 | 0.290 | ||||
| Lymph node status (absent vs. present) | 1.678 | 0.815–3.455 | 0.160 | ||||
| iTILs (high vs. low) | 0.584 | 0.185–1.846 | 0.360 | ||||
| sTILs (high vs. low) | 0.499 | 0.150–1.659 | 0.257 | ||||
| iCD4 (low vs. high) | 0.210 | 0.046–0.959 | 0.044* | 0.172 | 0.037–0.792 | 0.024* | |
| sCD4 (low vs. high) | 1.992 | 0.599–6.626 | 0.261 | ||||
| iCD8 (low vs. high) | 0.303 | 0.0082–1.119 | 0.073 | ||||
| sCD8 (low vs. high) | 0.213 | 0.058–0.785 | 0.020* | 0.225 | 0.061–0.836 | 0.026* | |
| iFOXP3 (low vs. high) | 0.333 | 0.090–1.230 | 0.099 | ||||
| sFOXP3 (low vs. high) | 5.804 | 1.265–26.62 | 0.024* | 7.426 | 1.596–34.552 | 0.011* | |
| Ratio of immune cells | |||||||
| iCD4/CD8 | 0.369 | 0.100–1.365 | 0.135 | ||||
| sCD4/CD8 | 1.362 | 1.049–1.769 | 0.021* | 1.003 | 0.650–1.549 | 0.988 | |
| iCD8/FOXP3 | 0.626 | 0.199–1.973 | 0.424 | ||||
| sCD8/FOXP3 | 0.200 | 0.065–0.616 | 0.005* | 0.130 | 0.025–0.669 | 0.015* | |
| iFOXP3/CD4 | 0.356 | 0.096–1.314 | 0.121 | ||||
| sFOXP3/CD4 | 1.858 | 1.160–2.977 | 0.010* | 2.766 | 1.443–5.302 | 0.002* | |
Multivariate cox regression analyses were performed for all potential variables that were significantly associated with survival in univariate analysis RFS recurrence-free survival. TNC triple-negative cancer, HR hazard ratio, CI confidence interval, i intratumoral, s stromal, TILs tumor-infiltrating
lymphocytes, FOXP3 Forkhead box P3
*P value is significant